Cytokines and neurotrophins in psychiatric disorders

Biomedical Reviews

Volumn 10, Issue 1, 1999, Pages 69-73

  Shintani, Futoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0348138180     PISSN: 1310392X     EISSN: None     Source Type: Journal    
DOI: 10.14748/bmr.v10.9     Document Type: Article

References (59)

1. Balkwill FR, Burke. The cytokine network. Immunol Today 1989; 9: 299-303.
2. Morganti-Kossmann MC, Kossmann T, Wahl SM. Cytokines and neuropathology. Trends Pharmacol Sci 1992; 13:286-291.
3. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2107.
4. Menkin V. Chemical basis of fever. Science 1944; 100:337-338.
5. Gowans JL. The recirculation of lymphocytes from blood to lymphintherat. J Physiol 1959; 146:54-69.
6. Kasakura S, Lovvenstein L. A factor stimulating DNA synthesis derived from the medium of leucocyte cultures. Nature 1965;208: 794-795.
7. Levi-Montalcini R. The saga of the nerve growth factor. NeuroReport 1998; 9: R71-R83.
8. Miller FD. Neuronal life or death: how do neurotrophins decide? Neural Notes 1998; 3: 3-7.
9. Nagtegaal ID, Lakke EAJF, Marani E. Trophic and tropic factors in the development of the central nervous system. Arch Physiol Biochein 1998; 106:161-202.
10. Schuman EM. Neurotrophin regulation of synaptic transmission. Curr Opin Neurobiol 1999; 9:105-109.
11. Heese K, Hock C, Otten U. Inflammatory signals induce neurotrophin expression in human microglial cells. J Neurochem 1998;70:699-707.
12. Marz P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U. Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia 1999; 26:191-200.
13. Aloe L, Bracci-Laudiero L, Bonini S, Manni L. The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy 1997; 52:883-894.
14. Woiciechowsky C, Schoning B, Lanksch WR, Volk H-D, Docke W-D. Mechanisms of brain-mediated systemic antiinflammatory syndrome causing immunodepression. J Mol Med 1999; 77:769-780.
15. Blalock JE. The syntax of immune-neuroedocrine communication. Immunol Today 1994; 15:504-511.
16. Anisman H, Baines MG, Berczi I, Bernstein CN, Blen-nerhassett MG, Gorczynski RM et al. Neuroimmune mechanisms in health and disease: 2. Disease. CMAJ 1996; 155: 1075-1082.
17. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, Nishihara M et al. Production of mice deficient in genes for interleukin (IL)-1 a, IL-1 β, IL-1 α/β, and IL-1 receptor antagonist shows that IL-lβ is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998; 187: 1463-1475.
18. Kamegai M, Niijima K, Kunishita T, Nishizawa M, Ogawa M, Araki M et al. Interleukin-3 as a trophic factor for central cholinergic neurons in vitro and in vivo. Neuron 1990; 4: 429-436. (Pubitemid 20155033)
19. Muller N, Ackenheil M. Psychoncuroimmunonology and the cytokine action in he CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1-33.
20. Weinberger DR. From neuropathology to ncurodcvclop-ment Lancet 1995; 346:552-557.
21. De Lisi E. Is schizophrenia a lifetime disorder of brain plasticity, growth and aging? Schizophr Res 1997; 23:119-129.
22. Holden RJ, Pakula IS. Immunological influences in attention-deficit disorder and schizophrenia; is there a link between these two conditions? Med Hypotheses 1995; 45: 575-87.
23. Shintani F, Nakaki T, Kanba S, Sato K, Yagi G, Shiozawa M et al. Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat. J Neurosci 1995; 15:1961-70.
24. Nguyen KT, Dcak T, Owens SM, Kohno T, Fleshner M, Watkins LR et al. Exposure to acute stress induces brain interleukin-lß, protein in the rat. J Neurosci 1998; 18:2239-46.
25. Shintani F, Kanba S, Maruo N, Nakaki T, Nibuya M, Suzuki E et al. Serum interleukin-6 in schizophrenic patients. Life Sci 1991;49:661-664.
26. Katila H, Appclberg B, Hurme M, Rimon R. Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr Res 1994; 12: 29-34.
27. Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994; 51:1-10.
28. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG et al. CSF IL-1 and IL-2 in medicated schizophrenic patients and in volunteers. Schizophr Res 1997; 25: 123-129.
29. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and intcrleukin-3 like activity in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1995:19:75-83.
30. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor in schizophrenia? Schizophr Res 1997; 26:227-233.
31. Kim YK, Lee MS, Suh KY. Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry 1998; 43:701-704.
32. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 1999; 37: 97-106.
33. Malek-Ahmadi P. Neuropsychiatric aspects of cytokine research. : an overview. Neurosci Biobehav Rev 1996; 20: 359-365.
34. Prolo P, Licinio J. Cytokines in affective disorders and schizophrenia: new clinical and genetic findings. Mol Psy-cltiatry 1999;4:109-111.
35. Suzuki E, Shintani F, Kanba S, Asai M, Nakaki T. Induction of interleukin-lß, and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci Lett 1996; 215:201-204.
36. Katila H, Hanninen K, Hurme M. Polymorphisms of the interleukin-l gene complex in schizophrenia. Mol Psychiatry 1999;4:179-181.
37. Fiore M, Talamini L, Angclucci F, Koch T, Aloe L, Korf J. Prental mcthylazoymethanol acetate alters behavior and brain NGF levels in young rats: a possible correlation with the development of schizophrenia-like deficits. Neuropharmacology 1999; 38:857-869.
38. Angelucci F, Cimino M, Balduini W, Pistillo L, Aloe L. Prenatal cthanol exposure causes differential effects in the nerve growth factor and its receptors in basal forebrain of preweaning and adult rats. J Neural Transpl Plasticity 1997; 6:63-71.
39. Nanko S, Hattori M, Kuwata S, Sasaki T, Fukuda R, Dai XY et al. Neurotroρhin-3 gene polymorphism associated with schizophrenia. Acta Psychiatr Scand 1994; 89: 390-392.
40. Dawson E, Powell JF, Sham PC, Nothen M, Crocq MA, Propping P et al. An association study of a ncurotrophin-3 (NT-3) gene polymorphism with schizophrenia. Acta Psychiatr Scand 1995; 92:425-428.
41. Sasaki T, Dai XY, Kuwata S, Fukuda R, Kunugi H, Hattori M et al. Brain-derived neurotrophic factor gene in schizophrenia in Japanese subjects. Am J Med Genet 1997; 74: 443-444.
42. Brusov OS, Zlobina GP, Nikolaeva EA, Ulas Vlu, Faktor MI, Pavlova OA et al. The indices of the thromocyte serotonin system and of the nerve grwoth factor system in children with hereditary disorders of neuropsychic development. Zh Neurol Psikhiatr Im SS Korsakova 1998; 98: 27-31 (In Russian).
43. Bersani G, Iannitelli A, Maselli P, Pancheri P, Aloe L, Angelucci F et al. Low nerve growth factor plasma levels in schizoprenic patients: a preliminary study. Schizophr Res 1999;37:201-203.
44. Wassink TH, Nelson JJ, Crowe RR, Andreasen NC. Heritability of BDNF alleles and their effect on brain morphology in schizophrenia. Am J Med Genet 1999; 88:724-728.
45. Alleva E, Delia Seta D, Cirulli F, Aloe L. Haloperidol treatment decreases nerve growth factor levels in the hypothalamus of adult mice. Prog Neuropsychopharmacol Biol Psychiatiy 1996; 20:483-489.
46. Aloe L, Iannitelli A, Bersani G, Alleva E, Angelucci F, Maselli P et al. Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite, effects to arousal. Neuropsychobiology 1997; 36: 65-68.
47. Licinio J, Wong M-L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive system, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999;4:317-327.
48. Maes M, Meltzcr IIY, Buckley P, Bosmans E. Plasma soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 1995; 244:325-329.
49. Kanba S, Manki H, Shintani F, Ohni Y, Yagi G, Asai M. Aberrant interlukin-2 receptor-mediated blastoformation of peripheral blood lymphocytes in a severe major depressive episode. Psychol Med 1998; 28:481-484.
50. Altar CA. Neurotrophins and depression. Trends Pharmacol Sci 1999; 20: 59-61.
51. Gall CM, Isackson PJ. Limbic seizures increase neuronal production of messenger RNA for nerve growth factor. Science 1989;245:758-761.
52. Takashi M, Hayashi S, Kakita A, Wakabayashi K, Fukuda M, Kameyama S et al. Patients with temporal lobe epilepsy show an increase in brain-derived neurotrophic factor protein and its correlation with neuropeptide Y. Brain Res 1999; 818:579-582.
53. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain-derived neurotrophic factor expression. Neuropsychopharmacology 1999;21:679-682.
54. Yamamoto H, Gurney ME. Human platelets contain brain-derived neurotrophic factor. J Neurosci 1990; 10:3469-3478.
55. Turrini P, Tirassa P, Vigneti E, Aloe L. A role of the thymus and thymosin-α1 in brain NGF levels and NGF receptor expression. J Neuroimmunol 1998; 82:64-72.
56. Turrini P, Aloe L. Evidence that endogenous thymosin alpha-1 is present in the rat central nervous system. Neurochemlnt 1999;35:463-470.
57. Elmquist JK, Maratos-Flier E, Saper CB, Flier JS. Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1998; 1:445-450.
58. Wiesner G, Vaz M, Collier G, Seals D, Kaye D, Jennings G et al. Leptin is released from the human brain: influence of adiposity and gender. J Clin Endocrinol Metab 1999; 84: 2270-2274.
59. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker O et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatiy 1998; 3:76-80.